Last reviewed · How we verify

NCT05919927: DBC

Diabetes and Cognitive Functions in Middle Age

Status unknown Last updated 27 June 2023
What this trial tests

trial in Diabetes Mellitus, Type 2 in 120 participants. Status unknown.

Timeline
7 June 2018
Primary endpoint
31 December 2022
30 December 2024

Quick facts

Lead sponsorTampere University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment120
Start date7 June 2018
Primary completion31 December 2022
Estimated completion30 December 2024
Sites1 location across Finland

Conditions studied

Sponsor

Tampere University Hospital

Who can join

Adults 35 to 65, any sex, with Diabetes Mellitus, Type 2 or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine the effects of type II diabetes on cognitive functions and mood in middle-aged patients. In addition, the association between cognitive functions and glycemic controls is studied in patients. Sixty patients and sixty healthy controls will be recruited and assessed by a multiprofessional team (neuropsychologist, physician).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other Tampere University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05919927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing